All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Bristol-Myers Squibb Challenges Patent on Merck's Pembrolizumab

September 5th 2014

BMS has filed a lawsuit over Merck's newly approved immunotherapy drug pembrolizumab, contending that the much-heralded PD-1 inhibitor will infringe upon patents that Bristol-Myers holds on the groundbreaking technology.

FDA Approves Pembrolizumab for Advanced Melanoma

September 4th 2014

The FDA has approved pembrolizumab (Keytruda) as a treatment for patients with advanced or unresectable melanoma who are no longer responding to other drugs, making it the first PD-1 inhibitor to gain approval in the United States.

Four Distinct Subtypes of Gastric Cancer Found

September 4th 2014

Gastric cancer is comprised of 4 distinct molecular subtypes of disease, each representing a unique opportunity for new drug development, according to a paper published in Nature by The Cancer Genome Atlas (TCGA).

Converting From Manual to Electronic Transactions Could Save Healthcare Industry Billions

September 4th 2014

A report issued by the Council for Affordable Quality Healthcare (CAQH) suggests that if providers and health plans converted fully from manual to electronic transactions, it could result in an additional estimated savings of $8.1 billion for the healthcare industry.

FDA Grants Priority Review to Lanreotide for GEP NETs

September 3rd 2014

The FDA has assigned a priority review designation to lanreotide (Somatuline Depot) as a treatment for patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)

ASCO Issues New Guideline for Advanced HER2-Negative Breast Cancer

September 3rd 2014

The American Society of Clinical Oncology (ASCO) has released a new clinical practice guideline on the treatment of patients with advanced HER2-negative breast cancer.

Negative Cabozantinib Prostate Study Triggers Massive Exelixis Restructuring

September 2nd 2014

Cabozantinib (Cometriq) failed to significantly extend overall survival compared with prednisone as a treatment for men with metastatic castration-resistant prostate cancer.

FDA Approval Sought for Lenvatinib in Differentiated Thyroid Cancer

August 31st 2014

Eisai has submitted a New Drug Application for lenvatinib (E7080) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase III SELECT trial that was presented at the 2014 ASCO Annual Meeting.

Advaxis Scientific Officer Illuminates ADXS-PSA/Pembrolizumab Collaborative Study

August 30th 2014

Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.

Pembrolizumab Combination Study Planned in Prostate Cancer

August 27th 2014

Advaxis and Merck have entered into a clinical trial collaboration agreement to evaluate the combination of two novel immunotherapies for the treatment of patients with metastatic castration-resistant prostate cancer.

CAR T Cell Therapy Effective in Advanced B-cell Malignancies

August 26th 2014

Treatment with KTE-C19, a CD19-targeted CAR-modified T cell therapy, demonstrated an objective response rate of 92% in patients with advanced B-cell malignancies.

FDA Approves Eltrombopag for Severe Aplastic Anemia

August 26th 2014

The FDA has approved eltrombopag as a treatment for patients with severe aplastic anemia following an insufficient response to immunosuppressive therapy.

Increased Medicaid Payments for Office Visits Results in More Screening for Cancer

August 26th 2014

Medicaid patients in states that pay more for office visits had an increased likelihood of being screened for cancer, according to results of a study published in CANCER.

Report Identifies Shortfalls in Medicare Accountability Model

August 25th 2014

How much physicians get paid is increasingly determined by a payment formula that penalizes doctors whose patients are more expensive-even when those higher costs stem from services that other doctors perform says a new report from the Center for Healthcare Quality and Payment Reform.

Pharma Collaborations Abound Across Oncology

August 21st 2014

A number of large pharmaceutical companies have forged clinical trial collaborations focused on the investigation of novel combinations and companion diagnostics across multiple cancer indications.

Lenalidomide Plus R-CHOP Effective in Aggressive DLBCL Subtype

August 19th 2014

The addition of lenalidomide to R-CHOP demonstrated promising efficacy in previously untreated patients with diffuse large B-cell lymphoma across all subtypes of the disease.

Using Technology to Improve Patient Fee Collection Rates

August 19th 2014

Although the Affordable Care Act (ACA) made accessibility to health insurance easier, consumers are finding themselves shouldering greater out-of-pocket costs in the form of copayments and deductibles for the care that they receive. Physicians are also feeling the need to collect more fees from more of their patients.

Medicare to Pay Docs for Chronic Care Coordination

August 18th 2014

Starting in January 2015, Medicare will begin paying physicians for the care coordination they provide beneficiaries with chronic conditions.

Pfizer Seeks FDA Approval for Palbociclib

August 18th 2014

Pfizer has submitted a New Drug Application for palbociclib plus letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative advanced breast cancer, based on findings from the phase II PALOMA-1 trial.

Medicaid and Uninsured Patients More Likely to Present With Advanced Disease

August 15th 2014

Patients with Medicaid insurance and those without insurance were more likely to present with distant disease than patients with private insurance, according to results presented in the Journal of Clinical Oncology.